CD8A and neoplasm: Consistently, TZ‐dSA3‐12 enhanced the production of effector molecules, including GzmB and IFN‐γ, by tumor‐infiltrating CD8+ T cells compared to monotherapy (Figure 8g,h), reinforcing its role in augmenting cytotoxic CD8+ T cells activity.